SPIRE: A phase Ib/randomised IIa open label clinical trial combining guadecitabine (SGI-110) with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.

SPIRE – combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial

Trials ◽

10.1186/s13063-018-2586-7 ◽

2018 ◽

Vol 19 (1) ◽

Cited By ~ 2

Author(s):

Simon Crabb ◽

Sarah J. Danson ◽

James W. F. Catto ◽

Cathy McDowell ◽

James N. Lowder ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Study Protocol ◽

Open Label ◽

Phase Ib ◽

Cancer Study ◽

SPIRE: A phase Ib/ randomised IIa open label clinical trial combining guadecitabine with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer

Annals of Oncology ◽

10.1093/annonc/mdy279.412 ◽

2018 ◽

Vol 29 ◽

pp. viii139

Author(s):

S.J. Crabb ◽

S.J. Danson ◽

D. Dunkley ◽

M. Kalevras ◽

A. Whitehead ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Open Label ◽

Phase Ib ◽

Faculty Opinions recommendation of Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.739122585.793581022 ◽

2020 ◽

Author(s):

Otto Hemminki

Keyword(s):

Clinical Trial ◽

Gene Therapy ◽

Bladder Cancer ◽

Invasive Bladder Cancer ◽

Repeat Dose ◽

Open Label ◽

A phase I open label dose‐escalation study to evaluate the tolerability, safety and immunological efficacy of sub‐urothelial durvalumab injection in adults with muscle‐invasive or high‐risk non‐muscle‐invasive bladder cancer (SUBDUE‐1, SUB‐urothelial DUrvalumab injection‐1 study): clinical trial protocol

BJU International ◽

10.1111/bju.15365 ◽

2021 ◽

Author(s):

Andrew Moe ◽

Elizabeth Liow ◽

Andrew Redfern ◽

Nicole Swarbrick ◽

Tom Ferguson ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

High Risk ◽

Phase I ◽

Trial Protocol ◽

Open Label ◽

Dose Escalation Study ◽

Label Dose ◽

44P Biomarker analysis from a phase Ib, multicenter, open-label clinical trial of talimogene laherparepvec (T-VEC) injected (inj) into metastatic and primary liver tumors

Annals of Oncology ◽

10.1016/j.annonc.2021.10.060 ◽

2021 ◽

Vol 32 ◽

pp. S1390-S1391

Author(s):

J.R. Hecht ◽

M. Peeters ◽

M. Martin Jimenez ◽

M. Pless ◽

A. Cubillo ◽

...

Keyword(s):

Clinical Trial ◽

Liver Tumors ◽

Talimogene Laherparepvec ◽

Open Label ◽

Phase Ib ◽

Primary Liver Tumors ◽

Biomarker Analysis

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30540-4 ◽

2021 ◽

Vol 22 (1) ◽

pp. 107-117 ◽

Cited By ~ 2

Author(s):

Stephen A Boorjian ◽

Mehrdad Alemozaffar ◽

Badrinath R Konety ◽

Neal D Shore ◽

Leonard G Gomella ◽

...

Keyword(s):

Clinical Trial ◽

Gene Therapy ◽

Bladder Cancer ◽

Invasive Bladder Cancer ◽

Repeat Dose ◽

Open Label ◽

A Phase Ib Open Label Clinical Trial of Continuous Once Daily Oral Afatinib (A) Plus Sirolimus (S) in Patients (Pts) with Egfr Mutation Positive (Egfr M+) Nsclc and/or Disease Progression Following Prior Erlotinib (E) or Gefitinib (G)

Annals of Oncology ◽

10.1093/annonc/mdu349.27 ◽

2014 ◽

Vol 25 ◽

pp. iv437 ◽

Cited By ~ 3

Author(s):

T. Moran ◽

R. Palmero ◽

M. Provencio ◽

A. Insa ◽

M. Majem ◽

...

Keyword(s):

Clinical Trial ◽

Disease Progression ◽

Egfr Mutation ◽

Open Label ◽

Once Daily ◽

Phase Ib

A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26 –104/ RFASE in Patients with Advanced Solid Malignancies

The Oncologist ◽

10.1002/onco.13576 ◽

2020 ◽

Author(s):

Ruben S.A. Goedegebuure ◽

Madelon Q. Wentink ◽

Hans J. Vliet ◽

Peter Timmerman ◽

Arjan W. Griffioen ◽

...

Keyword(s):

Clinical Trial ◽

Phase I ◽

Therapeutic Vaccine ◽

Open Label ◽

Re: Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-unresponsive Non-muscle-invasive Bladder Cancer: A Single-arm, Open-label, Repeat-dose Clinical Trial

European Urology ◽

10.1016/j.eururo.2021.01.027 ◽

2021 ◽

Author(s):

Francesco Soria ◽

Paolo Gontero

Keyword(s):

Clinical Trial ◽

Gene Therapy ◽

Bladder Cancer ◽

Invasive Bladder Cancer ◽

Repeat Dose ◽

Open Label ◽

Results of the phase-I open-label clinical trial SAKK 06/14 assessing safety of intravesical instillation of the recombinant BCG VPM1002BC in patients with non-muscle invasive bladder cancer and previous failure to conventional BCG therapy

European Urology Supplements ◽

10.1016/s1569-9056(18)31563-x ◽

2018 ◽

Vol 17 (2) ◽

pp. e1050 ◽

Cited By ~ 5

Author(s):

C. Rentsch ◽

P. Bosshard ◽

G. Mayor ◽

M. Rieken ◽

H. Püschel ◽

...

Keyword(s):

Clinical Trial ◽

Bladder Cancer ◽

Phase I ◽

Intravesical Instillation ◽

Invasive Bladder Cancer ◽

Open Label ◽

Bcg Therapy ◽

Muscle Invasive ◽

Recombinant Bcg